Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bexagliflozin Clear all
Recruiting Phase 4 Interventional

Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study

NCT05612594
View directory record Official record
Conditions
Sleep Apnea
Interventions
Bexagliflozin 20 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

NCT02956044
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin, Metformin, Glimepiride, Sitagliptin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

NCT02836873
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fresno, California • La Palma, California • Lincoln, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment

NCT03557658
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Boston, Massachusetts • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT03115112
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Sitagliptin, Placebo for sitagliptin, Placebo for bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Lincoln, California • Long Beach, California • San Dimas, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

NCT02820298
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT03259789
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin tablets, 20 mg, Bexagliflozin tablets, placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
26
States / cities
Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 2 Interventional Results available

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

NCT02390050
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Bexagliflozin tablets, Bexagliflozin tablets, placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Peoria, Arizona • Tucson, Arizona • Canoga Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

NCT02715258
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Canoga Park, California • Chino, California • Huntington Park, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability Study With Bexagliflozin

NCT03417076
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

NCT03514641
View directory record Official record
Conditions
Essential Hypertension
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
87
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Bexagliflozin Efficacy and Safety Trial

NCT02558296
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
40 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
66
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Azusa, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Not yet recruiting Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 4, 2026, 8:49 PM EDT
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

NCT03167411
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin, Exenatide Injection
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bexagliflozin Drug/Drug Interaction Study With Digoxin

NCT03197324
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin, Digoxin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

NCT01377844
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
EGT0001442, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 70 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Buena Park, California • Los Angeles, California • Santa Ana, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

NCT03296800
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Probenecid, Rifampin, Verapamil
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 4, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT02769481
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 4, 2026, 8:49 PM EDT